Resources and Evidence Contact us

Turning to nutrition to help address the complications of prematurity

Since 2012, the American Academy of Pediatrics has recommended human milk as the primary source of nutrition for preterm infants, with appropriate fortification for those born weighing <1.5 kg.1 Fortification with human milk–based fortifiers is the only way to ensure these medically fragile infants receive an exclusive human milk diet (EHMD).

Prolacta products used as a part of that Exclusive Human Milk Diet (EHMD),2 as compared to cow milk–based fortifiers, have been shown in clinical studies to benefit critically ill, premature infants in the Special Care Baby Unit (NICU) weighing ≤1250 g at birth in many ways including to:

  • Improve health outcomes3,4,5,6,7,8
  • Achieve adequate growth9,10,11
  • Reduce hospital costs6,12

Getting the most out of an Exclusive Human Milk Diet (EHMD)

Clinical value

Learn about cost savings, complication reductions and health outcomes associated with our products

Clinical evidence

Read peer-reviewed studies and clinical results

Peer support

Gain insights from fellow neonatologists, nurses and dietitians

Leading the human milk industry in quality and safety


First and only pharmaceutical-grade manufacturing facilities for the testing and processing of human milk


Exceed food-product industry requirements by following stringent quality and safety standards based on those for the human plasma and blood industry in the US

US Food and Drug Administration (FDA) regulated lab processes

Our human milk laboratory and manufacturing processes are regulated by the US Food and Drug Administration (FDA).

All Prolacta nutritional products are pasteurised to ensure the highest quality and safety, using time and temperature profiles defined by the US Food and Drug Administration (FDA) in its Pasteurised Milk Ordinance (PMO) to destroy pathogenic viruses and bacteria.

While there are other pasteurisation and sterilisation processes used in the human milk banking industry, only products manufactured with our pasteurisation process are clinically shown to improve health and reduce complications when used as part of an exclusive human milk diet (EHMD) in the neonatal intensive care unit (NICU). There is no clinical data showing similar results using products processed by any other method.

Benefits of human milk oligosaccharides (HMOs)

Prolacta’s 100% human milk–based nutritional products contain a wide spectrum of human milk oligosaccharides (HMOs).13 The immunity, prebiotic and gut maturation benefits that human milk oligosaccharides (HMOs) promote may have a role in the health outcomes attributed to an Exclusive Human Milk Diet (EHMD), including Prolacta’s products.14

To learn more

Improving health outcomes for premature infants

For more than two decades, we have been advancing the science of human milk to improve the health of premature, critically ill infants worldwide.

  • The clinical benefits of our products have been demonstrated in 20+ clinical trials studying 5000+ infants
  • Globally, more than 70,000 premature infants have benefitted from our proven human milk–based nutritional products*

A cost-effective solution

When used as part of an Exclusive Human Milk Diet (EHMD), our nutritional products are clinically proven to increase survival and reduce the overall cost of care compared to cow milk–based fortifiers or preterm formula in extremely premature infants.5,6

Tell us how we can help

Clinician-to-clinician guidance

Coding, billing and reimbursement questions

Finding my sales representative

Support with an order

*Estimated number of premature infants fed Prolacta’s products from January 2007 to May 2021; data on file.